Kinnov Therapeutics is focused on developing innovative strategies to address addiction, a significant socio-economic issue affecting over 35 million people globally. Their lead product, KT-110, has shown promise in phase II clinical trials for treating alcohol use disorder, demonstrating positive results in reducing total alcohol consumption among patients. The company has leveraged over 20 years of research into the pharmacological and biochemical mechanisms of addiction, leading to the identification of key receptors involved in addictive behaviors. This foundational research has enabled Kinnov to create a proprietary pharmaceutical composition that aims to be a first-in-class therapy for various addiction disorders.

In addition to KT-110, Kinnov Therapeutics has developed a novel galenic formulation that allows for a single daily intake, addressing adherence challenges in patients with alcohol dependency. The company holds multiple patents protecting their innovative compositions and combinations for treating addiction, which have been recognized in major markets, including the USA, Europe, and China. Kinnov's commitment to research and development is further evidenced by their participation in significant scientific congresses and collaborations with leading experts in addiction, reinforcing their position as a key player in the field of addiction treatment.

France

KINNOV was created as a spin off from Greenpharma and Key-Obs, both located in Orléans, 100 km south of Paris France.

Kinnov-Therapeutics founders have worked on deciphering the pharmacological and biochemical mechanisms of addiction for more than 20 years, resulting in the identification of a disruptive strategy to treat addicted people.

KT-110 is the first project based on this new strategy to positively complete a phase 2 trial.

KT-110 proof of concept clinical trial on alcohol addiction has started in nov 2019, results were available in January 2022. They were positive and very high risk level population is likely to be targeted for phase 3 study.

KINNOV THERAPEUTICS

Company Details